Matthew Sibley1, Abishek Roshan1, Alanoud Alshami1, Marisa Catapang1, Jasper J Jöbsis1, Trevor Kwok1, Nonnie Polderman1, Jennifer Sibley1, Douglas G Matsell1, Cherry Mammen2,3. 1. Division of Nephrology, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada. 2. Division of Nephrology, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada. cmammen@cw.bc.ca. 3. British Columbia Children's Hospital, 4480 Oak Street, Room K4-152, Vancouver, BC, V6H 3V4, Canada. cmammen@cw.bc.ca.
Abstract
BACKGROUND: Historically, children with nephrotic syndrome (NS) across British Columbia (BC), Canada have been cared for without formal standardization of induction prednisone dosing. We hypothesized that local historical practice variation in induction dosing was wide and that children treated with lower doses had worse relapsing outcomes. METHODS: This retrospective cohort study included 92 NS patients from BC Children's Hospital (1990-2010). We excluded secondary causes of NS, age < 1 year at diagnosis, steroid resistance, and incomplete induction due to early relapse. We explored cumulative induction dose and defined dosing quartiles. Relapsing outcomes above and below each quartile threshold were compared including total relapses in 2 years, time to first relapse, and proportions developing frequently relapsing NS (FRNS) or starting a steroid-sparing agent (SSA). RESULTS: Cumulative prednisone was widely distributed with approximated median, 1st, and 3rd quartile doses of 2500, 2000, and 3000 mg/m2 respectively. Doses ≤ 2000 mg/m2 showed significantly higher relapses (4.2 vs 2.7), shorter time to first relapse (61 vs 175 days), and higher SSA use (36 vs 14%) compared to higher doses. Doses ≤ 2500 mg/m2 also showed significantly more relapses (3.9 vs 2.2), quicker first relapse (79 vs 208 days), and higher FRNS (37 vs 17%) and SSA use (28 vs 11%). Relapsing outcomes lacked statistical difference in ≤ 3000 vs > 3000 mg/m2 doses. CONCLUSIONS: Results strongly justify our development of a standardized, province-wide NS clinical pathway to reduce practice variation and minimize under-treatment. The lowest induction prednisone dosing threshold to minimize future relapsing risks is likely between 2000 and 2500 mg/m2. Further prospective studies are warranted.
BACKGROUND: Historically, children with nephrotic syndrome (NS) across British Columbia (BC), Canada have been cared for without formal standardization of induction prednisone dosing. We hypothesized that local historical practice variation in induction dosing was wide and that children treated with lower doses had worse relapsing outcomes. METHODS: This retrospective cohort study included 92 NS patients from BC Children's Hospital (1990-2010). We excluded secondary causes of NS, age < 1 year at diagnosis, steroid resistance, and incomplete induction due to early relapse. We explored cumulative induction dose and defined dosing quartiles. Relapsing outcomes above and below each quartile threshold were compared including total relapses in 2 years, time to first relapse, and proportions developing frequently relapsing NS (FRNS) or starting a steroid-sparing agent (SSA). RESULTS: Cumulative prednisone was widely distributed with approximated median, 1st, and 3rd quartile doses of 2500, 2000, and 3000 mg/m2 respectively. Doses ≤ 2000 mg/m2 showed significantly higher relapses (4.2 vs 2.7), shorter time to first relapse (61 vs 175 days), and higher SSA use (36 vs 14%) compared to higher doses. Doses ≤ 2500 mg/m2 also showed significantly more relapses (3.9 vs 2.2), quicker first relapse (79 vs 208 days), and higher FRNS (37 vs 17%) and SSA use (28 vs 11%). Relapsing outcomes lacked statistical difference in ≤ 3000 vs > 3000 mg/m2 doses. CONCLUSIONS: Results strongly justify our development of a standardized, province-wide NS clinical pathway to reduce practice variation and minimize under-treatment. The lowest induction prednisone dosing threshold to minimize future relapsing risks is likely between 2000 and 2500 mg/m2. Further prospective studies are warranted.
Entities:
Keywords:
Childhood; Minimal change disease; Nephrotic syndrome; Practice variation; Prednisone
Authors: Nynke Teeninga; Joana E Kist-van Holthe; Nienske van Rijswijk; Nienke I de Mos; Wim C J Hop; Jack F M Wetzels; Albert J van der Heijden; Jeroen Nauta Journal: J Am Soc Nephrol Date: 2013-01 Impact factor: 10.121
Authors: Nathaniel MacHardy; Paul V Miles; Susan F Massengill; William E Smoyer; John D Mahan; Larry Greenbaum; Sara Massie; Lynne Yao; Shashi Nagaraj; Jen-Jar Lin; Delbert Wigfall; Howard Trachtman; Yichun Hu; Debbie S Gipson Journal: Pediatr Nephrol Date: 2009-08-12 Impact factor: 3.714
Authors: Loubna El Bakkali; Robert Rodrigues Pereira; Dirk J Kuik; Johannes C F Ket; Joanna A E van Wijk Journal: Pediatr Nephrol Date: 2011-05-01 Impact factor: 3.714
Authors: Dora Liu; Alexandra Ahmet; Leanne Ward; Preetha Krishnamoorthy; Efrem D Mandelcorn; Richard Leigh; Jacques P Brown; Albert Cohen; Harold Kim Journal: Allergy Asthma Clin Immunol Date: 2013-08-15 Impact factor: 3.406
Authors: Andrea Pasini; Cristina Bertulli; Luca Casadio; Ciro Corrado; Alberto Edefonti; GianMarco Ghiggeri; Luciana Ghio; Mario Giordano; Claudio La Scola; Cristina Malaventura; Silvio Maringhini; Antonio P Mastrangelo; Marco Materassi; Francesca Mencarelli; Giovanni Messina; Elena Monti; William Morello; Giuseppe Puccio; Paola Romagnani; Giovanni Montini Journal: Front Pediatr Date: 2021-07-08 Impact factor: 3.418